{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:36:43Z","timestamp":1760524603134},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1700","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve \u2013 Arcutis) for topical treatment of seborrheic dermatitis in patients \u22659 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication.<\/jats:p>","DOI":"10.58347\/tml.2024.1700a","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:19:37Z","timestamp":1711991977000},"page":"57-59","source":"Crossref","is-referenced-by-count":2,"title":["Roflumilast Foam (Zoryve) for Seborrheic Dermatitis"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,4,15]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:19:38Z","timestamp":1711991978000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1700a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":0,"journal-issue":{"issue":"1700","published-online":{"date-parts":[[2024,4,15]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1700a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}